May 27
2025
Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 5
2025
Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Feb 19
2025
Phanes Therapeutics announces first patient dosed in clinical study of peluntamig (PT217) in combination with chemotherapy
SAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Dec 4
2024
Phanes Therapeutics’ PT217 granted Fast Track designation by the FDA for NEPC
This is the second Fast Track Designation granted to PT217 by the agency SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Phanes Therapeutics,...
Read More
Nov 6
2024
Phanes Therapeutics announces the appointment of gastrointestinal oncologist Prof. Zev Wainberg to its Clinical Advisory Board
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Oct 8
2024
Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 9
2024
Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with chemotherapy
SAN DIEGO, Sept. 9, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Aug 16
2024
Phanes Therapeutics’ PT217 receives Orphan Drug designation for neuroendocrine carcinoma from the FDA
SAN DIEGO, Aug. 16, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 8
2024
Phanes Therapeutics, Inc. announces clinical supply agreement with Roche to evaluate PT217 in combination with an anti-PD-L1 therapy
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on...
Read More
Apr 9
2024
Phanes Therapeutics’ PT217 granted Fast Track designation by the FDA
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
